Log in

NASDAQ:QTRX - Quanterix Stock Price, Forecast & News

$25.03
-0.13 (-0.52 %)
(As of 12/10/2019 03:04 AM ET)
Today's Range
$24.60
Now: $25.03
$25.44
50-Day Range
$19.16
MA: $22.99
$25.52
52-Week Range
$17.08
Now: $25.03
$36.15
Volume78,100 shs
Average Volume154,443 shs
Market Capitalization$701.22 million
P/E RatioN/A
Dividend YieldN/A
Beta1.36
Quanterix Corporation, a life sciences company, develops and markets ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Simoa HD-1 instrument, a sensitive automated multiplex protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection technology in various applications, including direct detection of nucleic acids. Read More…

Industry, Sector and Symbol

Industry Analytical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:QTRX
CUSIPN/A
Phone617-301-9400

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$37.63 million
Book Value$1.85 per share

Profitability

Net Income$-31,540,000.00

Miscellaneous

Employees177
Market Cap$701.22 million
Next Earnings Date3/16/2020 (Estimated)
OptionableNot Optionable

Receive QTRX News and Ratings via Email

Sign-up to receive the latest news and ratings for QTRX and its competitors with MarketBeat's FREE daily newsletter.


Quanterix (NASDAQ:QTRX) Frequently Asked Questions

What is Quanterix's stock symbol?

Quanterix trades on the NASDAQ under the ticker symbol "QTRX."

How were Quanterix's earnings last quarter?

Quanterix Corp (NASDAQ:QTRX) released its earnings results on Friday, November, 8th. The company reported ($0.37) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.38) by $0.01. The company had revenue of $14.94 million for the quarter, compared to analysts' expectations of $12.52 million. Quanterix had a negative return on equity of 54.74% and a negative net margin of 75.78%. View Quanterix's Earnings History.

When is Quanterix's next earnings date?

Quanterix is scheduled to release their next quarterly earnings announcement on Monday, March 16th 2020. View Earnings Estimates for Quanterix.

What price target have analysts set for QTRX?

2 brokers have issued 12 month price objectives for Quanterix's stock. Their forecasts range from $35.00 to $35.00. On average, they expect Quanterix's share price to reach $35.00 in the next year. This suggests a possible upside of 39.8% from the stock's current price. View Analyst Price Targets for Quanterix.

What is the consensus analysts' recommendation for Quanterix?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Quanterix in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Quanterix.

What are Wall Street analysts saying about Quanterix stock?

Here are some recent quotes from research analysts about Quanterix stock:
  • 1. According to Zacks Investment Research, "Quanterix Corporation is a developer of tools in high definition diagnostics. The Company focuses on research and diagnostics for brain injuries, heart disease, cancer and other diseases with its technology. It offers Simoa consumables, which include Simoa Discs, Simoa Cuvettes, Simoa Sealing Oil, Simoa Buffers and Disposable Tips. The company services include Simoa Accelerator Lab and custom assay development services. Quanterix Corporation is based in LEXINGTON, United States. " (11/26/2019)
  • 2. Canaccord Genuity analysts commented, "We come away feeling good about the momentum building, as QTRX is ~3% penetrated into the life sciences research market. QTRX is executing well above its 40%+ rev. growth target, and sits on new product launches. We reiterate our BUY, raise our PT to $38 from $35. One competitor just shut its doors. We were recently surprised to hear directly from privately-held Singulex CEO Guido Baechler (who employed 71 people and invested $225M+ into its business) that the company shuttered its business on June 28, 2019. With one less competitor, we expect QTRX to continue steamrolling ahead. QTRX is well positioned for elite growth. QTRX has grown its top line +70% in its trailing four quarters and is now rolling out new products, and feels good about Street’s $50.7M (+35%) estimate for 2019." (7/24/2019)

Has Quanterix been receiving favorable news coverage?

Media headlines about QTRX stock have been trending neutral recently, InfoTrie Sentiment reports. The research firm rates the sentiment of media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Quanterix earned a media sentiment score of 0.3 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Quanterix.

Are investors shorting Quanterix?

Quanterix saw a increase in short interest in November. As of November 15th, there was short interest totalling 1,200,000 shares, an increase of 8.1% from the October 31st total of 1,110,000 shares. Based on an average daily volume of 217,700 shares, the short-interest ratio is currently 5.5 days. Approximately 7.9% of the company's stock are sold short. View Quanterix's Current Options Chain.

Who are some of Quanterix's key competitors?

What other stocks do shareholders of Quanterix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Quanterix investors own include Allena Pharmaceuticals (ALNA), Spero Therapeutics (SPRO), Veracyte (VCYT), Akoustis Technologies (AKTS), Ardelyx (ARDX), Cara Therapeutics (CARA), Crispr Therapeutics (CRSP), Editas Medicine (EDIT), Illumina (ILMN) and ADT (ADT).

Who are Quanterix's key executives?

Quanterix's management team includes the folowing people:
  • Mr. E. Kevin Hrusovsky, Chairman, Pres & CEO (Age 58)
  • Dr. David R. Walt, Co-Founder, Chairman of Scientific Advisory Board & Director (Age 66)
  • Dr. David C. Duffy Ph.D., Sr. VP of R&D and CTO (Age 48)
  • Mr. Amol Chaubal, Chief Financial Officer (Age 43)
  • Mr. Bruce J. Bal, VP of Operations, Service & Quality (Age 60)

When did Quanterix IPO?

(QTRX) raised $50 million in an IPO on Thursday, December 7th 2017. The company issued 3,300,000 shares at $14.00-$16.00 per share. J.P. Morga and Leerink Partners served as the underwriters for the IPO and BTIG and Evercore ISI were co-managers.

Who are Quanterix's major shareholders?

Quanterix's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Millennium Management LLC (1.71%), Ashford Capital Management Inc. (1.63%), State Street Corp (0.75%), Kornitzer Capital Management Inc. KS (0.65%), Essex Investment Management Co. LLC (0.52%) and State of Michigan Retirement System (0.40%). Company insiders that own Quanterix stock include David C Duffy, David R Walt, Dawn Mattoon, E Kevin Hrusovsky, Ernest Orticerio, John M Connolly, Joseph Driscoll, Marijn E Dekkers, Mark T Roskey, Martin D Madaus and Venture Fund Viii Overage Arch. View Institutional Ownership Trends for Quanterix.

Which institutional investors are selling Quanterix stock?

QTRX stock was sold by a variety of institutional investors in the last quarter, including Steward Partners Investment Advisory LLC. Company insiders that have sold Quanterix company stock in the last year include David C Duffy, Dawn Mattoon, E Kevin Hrusovsky, Ernest Orticerio, Joseph Driscoll, Marijn E Dekkers, Mark T Roskey and Martin D Madaus. View Insider Buying and Selling for Quanterix.

Which institutional investors are buying Quanterix stock?

QTRX stock was acquired by a variety of institutional investors in the last quarter, including Kornitzer Capital Management Inc. KS, State of Michigan Retirement System, Granahan Investment Management Inc. MA, Essex Investment Management Co. LLC, Millennium Management LLC, Ashford Capital Management Inc., Carnegie Capital Asset Management LLC and Barclays PLC. Company insiders that have bought Quanterix stock in the last two years include David R Walt, E Kevin Hrusovsky, John M Connolly and Venture Fund Viii Overage Arch. View Insider Buying and Selling for Quanterix.

How do I buy shares of Quanterix?

Shares of QTRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Quanterix's stock price today?

One share of QTRX stock can currently be purchased for approximately $25.03.

How big of a company is Quanterix?

Quanterix has a market capitalization of $701.22 million and generates $37.63 million in revenue each year. The company earns $-31,540,000.00 in net income (profit) each year or ($1.43) on an earnings per share basis. Quanterix employs 177 workers across the globe.View Additional Information About Quanterix.

What is Quanterix's official website?

The official website for Quanterix is http://www.quanterix.com/.

How can I contact Quanterix?

Quanterix's mailing address is 900 MIDDLESEX TURNPIKE, BILLERICA MA, 01821. The company can be reached via phone at 617-301-9400.


MarketBeat Community Rating for Quanterix (NASDAQ QTRX)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  214 (Vote Outperform)
Underperform Votes:  244 (Vote Underperform)
Total Votes:  458
MarketBeat's community ratings are surveys of what our community members think about Quanterix and other stocks. Vote "Outperform" if you believe QTRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe QTRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/10/2019 by MarketBeat.com Staff

Featured Article: What is a resistance level?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel